Advanced Enzyme Technologies has reported its financial results for the quarter and financial year ended March 31, 2026, reflecting robust growth. The Board has recommended a final dividend of ₹1.35 per share, representing 67.5% on the face value of ₹2. Additionally, the company announced key leadership reappointments and organizational updates, including the appointment of an additional independent director and the reappointment of its statutory auditors for a new five-year term.
Financial Performance Overview
For the financial year ended March 31, 2026, the company delivered a strong performance with total consolidated income reaching ₹7,805.89 million, compared to ₹6,699.51 million in the previous year. The net profit attributable to shareholders for the year stood at ₹1,687.19 million, a significant increase from ₹1,311.15 million reported in the prior fiscal year. On a quarterly basis, the consolidated income for the quarter ended March 31, 2026, was ₹2,105.95 million.
Dividend and Strategic Decisions
The Board of Directors has recommended a final dividend of ₹1.35 per equity share, subject to approval by shareholders at the 37th Annual General Meeting. Furthermore, the company has decided to defer the declaration of an interim dividend to prioritize capital preservation, ensuring the flexibility to pursue strategic avenues and corporate actions aimed at maximizing long-term shareholder value.
Leadership and Governance Updates
In a move to strengthen corporate governance, the Board has approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for a five-year term effective April 01, 2027. Additionally, Mr. Pradip Bhailal Shah has been appointed as an Additional Director (Independent) for a five-year term effective June 12, 2026. The company also confirmed the reappointment of M S K A & Associates LLP as statutory auditors for a second consecutive five-year term.
Operational Highlights
The company continues to focus on its core business segment of manufacturing and sales of enzymes. During the year, the company allotted 49,350 equity shares under the Employees Stock Options Scheme 2022. Moreover, a new wholly-owned subsidiary, Advanced Nutrazyme Private Limited, was incorporated in July 2025 to expand the company’s reach in the nutrition and wellness product market.
Source: BSE
